Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Cryofocus Medtech Shanghai Co Ltd

6922:HKG.HS

Cryofocus Medtech Shanghai Co Ltd

Actions
  • Price (HKD)7.66
  • Today's Change0.64 / 9.12%
  • Shares traded9.60k
  • 1 Year change-59.47%
  • Beta--
Data delayed at least 15 minutes, as of Oct 15 2024 07:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cryofocus Medtech Shanghai Co Ltd is a China-based medical device company, focusing on the research, development and commercialization of cryotherapy devices. The Company has built a comprehensive product portfolio comprising two core products, approximately 15 other product candidates in various development stages as well as approximately six additional commercialized medical consumables. The two core products comprise the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Company's products mainly target two therapeutic areas: natural orifice transluminal endoscopic surgery, to treat urinary, respiratory, and digestive diseases (such as bladder cancer, COPD, asthma, airway stenosis, gastric cancer, esophageal cancer and others), and vascular interventional therapy to treat cardiovascular diseases (such as atrial fibrillation, hypertension and others).

  • Revenue in HKD (TTM)45.33m
  • Net income in HKD-116.03m
  • Incorporated2013
  • Employees370.00
  • Location
    Cryofocus Medtech Shanghai Co LtdLane 3399Kangxin Highway, Pudong New AreaSHANGHAI 201318ChinaCHN
  • Phone+86 2 120977850
  • Websitehttps://www.cryofocus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.